-
公开(公告)号：EP3088419A1
公开(公告)日：2016-11-02
申请号：EP14874745.4
申请日：2014-12-24
发明人： AGATSUMA, Toshinori , TAKAHASHI, Shu , HASEGAWA, Jun , OKAJIMA, Daisuke , HAMADA, Hirofumi , YAMAGUCHI, Miki
IPC分类号： C07K16/28 , A61K31/4745 , A61K39/395 , A61K47/48 , A61P35/00 , C12N15/09
CPC分类号： C07K16/30 , A61K31/4745 , A61K47/6803 , A61K47/6851 , A61K47/6857 , A61K47/6859 , A61K47/6863 , A61K47/6865 , A61K47/6869 , A61K47/6889 , C07K16/3023 , C07K16/303 , C07K16/3046 , C07K16/3053 , C07K16/3069 , C07K2317/24 , C07K2317/77 , C07K2317/92
摘要： It is intended to provide an antitumor drug having an excellent therapeutic effect, which is excellent in terms of antitumor effect and safety. There is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an anti-TROP2 antibody via a linker having a structure represented by the following formula: -L 1 -L 2 -L P -NH-(CH 2 )n 1 -L a -(CH 2 )n 2 -C(=O)- wherein the anti-TROP2 antibody is connected to the terminal of L 1 , and the antitumor compound is connected to the carbonyl group of the -(CH 2 )n 2 -C(=O)- moiety with the nitrogen atom of the amino group at position 1 as a connecting position.
-
公开(公告)号：EP3088419B1
公开(公告)日：2018-10-10
申请号：EP14874745.4
申请日：2014-12-24
发明人： AGATSUMA, Toshinori , TAKAHASHI, Shu , HASEGAWA, Jun , OKAJIMA, Daisuke , HAMADA, Hirofumi , YAMAGUCHI, Miki
IPC分类号： C07K16/28 , A61K31/4745 , A61K39/395 , A61K47/68 , A61P35/00 , C12N15/09 , C07K16/30
CPC分类号： C07K16/30 , A61K31/4745 , A61K47/6803 , A61K47/6851 , A61K47/6857 , A61K47/6859 , A61K47/6863 , A61K47/6865 , A61K47/6869 , A61K47/6889 , C07K16/3023 , C07K16/303 , C07K16/3046 , C07K16/3053 , C07K16/3069 , C07K2317/24 , C07K2317/77 , C07K2317/92
摘要： It is intended to provide an antitumor drug having an excellent therapeutic effect, which is excellent in terms of antitumor effect and safety. There is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an anti-TROP2 antibody via a linker having a structure represented by the following formula: -L 1 -L 2 -L P -NH-(CH 2 )n 1 -L a -(CH 2 )n 2 -C(=O)- wherein the anti-TROP2 antibody is connected to the terminal of L 1 , and the antitumor compound is connected to the carbonyl group of the -(CH 2 )n 2 -C(=O)- moiety with the nitrogen atom of the amino group at position 1 as a connecting position.
-
公开(公告)号：EP2625205A2
公开(公告)日：2013-08-14
申请号：EP11778519.6
申请日：2011-10-04
发明人： WATANABE, Ichiro , HIRUMA, Yoshiharu , TSUDA, Eisuke , MATSUOKA, Tatsuji , OHTSUKA, Toshiaki , TAKAHASHI, Tohru , AGATSUMA, Toshinori , MILLER, Sandra , MÜHLBACHER, Robert , BAEHS, Kathrin-Ladetzki , RUNZ, Steffen , SCHUBERT, Ulrike , SCHUSTER, Ingrid , PONSEL, Dirk
IPC分类号： C07K16/28
CPC分类号： A61K39/3955 , A61K45/06 , A61K2039/505 , C07K16/2803 , C07K2317/21 , C07K2317/55 , C07K2317/92
摘要： An isolated antibody capable of binding Siglec-15 which inhibits osteoclast formation and/or osteoclastic bone resorption, or a functional fragment thereof. The heavy chain of the antibody comprises a CDRH1 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 106, a CDRH2 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 107, and a CDRH3 comprising a sequence having at least 80% sequence identity to one of SEQ ID NOS: 35, 45, 55, 65 or 80. The light chain of the antibody comprises a CDRL1 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 73 or 83, a CDRL2 comprising a sequence having at least 80% sequence identity to SEQ ID NO: 108, and a CDRL3 comprising a sequence having at least 80% sequence identity to one of SEQ ID NOS: 40, 50, 60, 70, 90, 100 or 109.
-
公开(公告)号：EP2837685B1
公开(公告)日：2020-09-09
申请号：EP13776053.4
申请日：2013-04-09
-
公开(公告)号：EP2837685A1
公开(公告)日：2015-02-18
申请号：EP13776053.4
申请日：2013-04-09
发明人： OHTSUKA, Toshiaki , YOSHIMURA, Chigusa , AGATSUMA, Toshinori , URANO, Atsushi , KIMURA, Takako , MATSUI, Yumi , MATSUOKA, Tatsuji , HASEGAWA, Jun , KAMAI, Yasuki , KAWAIDA, Reimi
IPC分类号： C12N15/09 , A61K39/395 , A61P35/00 , C07K16/28 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12P21/08 , G01N33/574
摘要： The present invention provides an antibody which binds to a fibroblast growth factor receptor.
摘要翻译： 本发明提供了结合成纤维细胞生长因子受体的抗体。
-
公开(公告)号：EP2396084B1
公开(公告)日：2016-05-11
申请号：EP10710107.3
申请日：2010-02-10
发明人： KAWAIDA, Reimi , OHTSUKA, Toshiaki , AGATSUMA, Toshinori , RODLEY, Philip , MILLER, Sandra , SCHUBERT, Ulrike
CPC分类号： C07K16/2863 , A61K39/39558 , A61K2039/505 , C07K2317/21 , C07K2317/24 , C07K2317/33 , C07K2317/55 , C07K2317/565 , G01N2333/9121
-
公开(公告)号：EP2396084A1
公开(公告)日：2011-12-21
申请号：EP10710107.3
申请日：2010-02-10
发明人： KAWAIDA, Reimi , OHTSUKA, Toshiaki , AGATSUMA, Toshinori , RODLEY, Philip , MILLER, Sandra , SCHUBERT, Ulrike
CPC分类号： C07K16/2863 , A61K39/39558 , A61K2039/505 , C07K2317/21 , C07K2317/24 , C07K2317/33 , C07K2317/55 , C07K2317/565 , G01N2333/9121
摘要： The present disclosure provides recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for MST1R, which plays an integral role in various disorders or conditions, such as cancer. These antibodies, accordingly, can be used to treat these and other disorders and conditions. Antibodies of the disclosure also can be used in the diagnostics field, as well as for further investigating the role of MST1R in the progression of disorders associated with tumors. The disclosure also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use.
-
-
-
-
-
-
搜索结果
7 条记录 (耗时 0.016 秒)
